Hortobagyi GN - Search Results

1

Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.

Han Y, Chen MK, Wang HL, Hsu JL, Li CW, Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC. Han Y, et al. Among authors: hortobagyi gn. Am J Cancer Res. 2019 Mar 1;9(3):608-618. eCollection 2019. Am J Cancer Res. 2019. PMID: 30949414 Free PMC article.

2

Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma.

Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M. Ro J, et al. Among authors: hortobagyi gn. Cancer Res. 1988 Jan 1;48(1):161-4. Cancer Res. 1988. PMID: 3334990

3

The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.

Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. Chang JY, et al. Among authors: hortobagyi gn. Oncogene. 1997 Feb 6;14(5):561-8. doi: 10.1038/sj.onc.1200861. Oncogene. 1997. PMID: 9053854

4

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.

Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Yu D, et al. Among authors: hortobagyi gn. Oncogene. 1998 Apr 23;16(16):2087-94. doi: 10.1038/sj.onc.1201729. Oncogene. 1998. PMID: 9572489

5

Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.

Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC. Zhang L, et al. Among authors: hortobagyi gn. Oncogene. 1998 Jun 4;16(22):2855-63. doi: 10.1038/sj.onc.1201813. Oncogene. 1998. PMID: 9671406

6

A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.

Hortobagyi GN, Hung MC, Lopez-Berestein G. Hortobagyi GN, et al. Hum Gene Ther. 1998 Aug 10;9(12):1775-98. doi: 10.1089/hum.1998.9.12-1775. Hum Gene Ther. 1998. PMID: 9721088 Clinical Trial. No abstract available.

7

Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Zhang L, et al. Among authors: hortobagyi gn. Clin Cancer Res. 1999 Feb;5(2):343-53. Clin Cancer Res. 1999. PMID: 10037184

8

Recent developments in breast cancer therapy.

Hortobagyi GN, Hung MC, Buzdar AU. Hortobagyi GN, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):11-20. Semin Oncol. 1999. PMID: 10482190 Review.

9

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Among authors: hortobagyi gn. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

10

Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer.

Hung MC, Hortobagyi GN, Ueno NT. Hung MC, et al. Among authors: hortobagyi gn. Adv Exp Med Biol. 2000;465:171-80. doi: 10.1007/0-306-46817-4_16. Adv Exp Med Biol. 2000. PMID: 10810625 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,108 results

Search Page

Filters